Abstract：
OBJECTIVE: To describe our clinical experience of endovascular exclusion of popliteal artery aneurysms using the new self-expandable covered stent SOLARIS® (Scitech Medical, Brazil), and to report its results in the context of surgical and endovascular treatment of popliteal artery aneurysms.
METHODS: Among 20 popliteal artery aneurysms undergoing open or endovascular repair in 2022 and 2023, two patients were successfully treated with the Solaris stentgraft. Both patients had a patent popliteal artery and three run-off vessels. After stentgraft implantation, they received dual antiplatelet therapy for three months and they were followed-up with Duplex scan and clinical evaluation after three months, and every six months thereafter. After three months, one Solaris stentgraft had complete thrombosis and the other ruptured, requiring surgical removal. No complications were observed among the other aneurysms treated with open repair or with the Viabahn® stentgraft.
CONCLUSIONS: Endovascular treatment of popliteal aneurysms with the new covered self-expandable stent Solaris resulted in severe complications in the two cases reported, and in worse short-term outcomes than endovascular repair with Viabahn® and open repair. Its off-label use to treat popliteal artery aneurysms should be therefore discouraged.
METHODS: Among 20 popliteal artery aneurysms undergoing open or endovascular repair in 2022 and 2023, two patients were successfully treated with the Solaris stentgraft. Both patients had a patent popliteal artery and three run-off vessels. After stentgraft implantation, they received dual antiplatelet therapy for three months and they were followed-up with Duplex scan and clinical evaluation after three months, and every six months thereafter. After three months, one Solaris stentgraft had complete thrombosis and the other ruptured, requiring surgical removal. No complications were observed among the other aneurysms treated with open repair or with the Viabahn® stentgraft.
CONCLUSIONS: Endovascular treatment of popliteal aneurysms with the new covered self-expandable stent Solaris resulted in severe complications in the two cases reported, and in worse short-term outcomes than endovascular repair with Viabahn® and open repair. Its off-label use to treat popliteal artery aneurysms should be therefore discouraged.
摘要：
目的：描述我们使用新型自膨式覆膜支架SOLARIS®（ScitechMedical，巴西),并报告其在手术和血管内治疗the动脉动脉瘤的情况下的结果。
方法：在2022年和2023年接受开放或血管内修复的20例pop动脉动脉瘤中，两名患者成功接受了Solaris支架移植物治疗。两名患者都有一条pop动脉和三条径流血管。支架移植后，他们接受了三个月的双重抗血小板治疗，三个月后接受了Duplex扫描和临床评估的随访，此后每六个月。三个月后,一个Solaris支架移植物完全血栓形成，另一个破裂，需要手术切除.在开放修复或Viabahn®支架移植物治疗的其他动脉瘤中未观察到并发症。
结论：新的覆膜自膨式Solaris支架血管内治疗动脉动脉动脉瘤在2例报告中导致严重的并发症，与Viabahn®和开放修复相比，短期结果更差。因此，不建议将其用于治疗the动脉动脉瘤。
方法：在2022年和2023年接受开放或血管内修复的20例pop动脉动脉瘤中，两名患者成功接受了Solaris支架移植物治疗。两名患者都有一条pop动脉和三条径流血管。支架移植后，他们接受了三个月的双重抗血小板治疗，三个月后接受了Duplex扫描和临床评估的随访，此后每六个月。三个月后,一个Solaris支架移植物完全血栓形成，另一个破裂，需要手术切除.在开放修复或Viabahn®支架移植物治疗的其他动脉瘤中未观察到并发症。
结论：新的覆膜自膨式Solaris支架血管内治疗动脉动脉动脉瘤在2例报告中导致严重的并发症，与Viabahn®和开放修复相比，短期结果更差。因此，不建议将其用于治疗the动脉动脉瘤。
